United States: During the time when COVID-19 and its subvariants became a matter of concern, health experts suggested an antibody that would help neutralize the known variants of the virus that are responsible for causing COVID-19. Along with this, the discovered antibody will also provide protection against the coronaviruses that could infect humans and other animals.
The antibody has been termed SC27 and was discovered by a team of researchers who were working on a new study on hybrid immunity to the virus. The study has been conducted by experts after several years of research on the antibody response, according to futurity.org.
While conducting the study, the researchers noticed the exact molecular sequence of the antibody, which opened the possibility of manufacturing it on a larger scale in the future.
One of the lead researchers and the assistant professor in the Cockrell School of Engineering’s McKetta chemical engineering department at the University of Texas – Jason Lavinder, stated, “The discovery of SC27, and other antibodies like it in the future, will help us better protect the population against current and future COVID variants.”
In the time since COVID-19 first emerged over four years ago, the virus has undergone swift and significant mutations. Each new variant has introduced distinct traits, many of which have bolstered its resistance to vaccines and therapeutic interventions, as per futurity.org.
Protective antibodies target a region of the virus known as the spike protein, a critical structure that facilitates the virus’s attachment to and invasion of human cells. By binding to this spike protein, the antibodies obstruct its ability to engage with cells, thereby halting the infection process.
SC27 has exhibited the ability to identify the evolving attributes of the spike proteins across a spectrum of COVID variants. This capability was affirmed by researchers at UT, who initially decoded the original spike protein’s structure and thus laid the groundwork for vaccine and treatment development.
The Ig-Seq technology employed to isolate this antibody grants scientists enhanced insight into the immune system’s response to both infection and vaccination. This advanced methodology integrates single-cell DNA sequencing with proteomic analysis.
“One of the overarching objectives in this field, particularly in vaccinology, is to pursue a universal vaccine that can elicit antibodies capable of producing an immune response broad enough to shield against a virus that rapidly mutates,” explains Will Voss, a recent PhD graduate in cell and molecular biology at UT’s College of Natural Sciences and co-leader of the study, as per the reports by futurity.org.
Alongside the identification of this antibody, the study also revealed that hybrid immunity—a fusion of natural infection and vaccination—yields a heightened level of antibody-mediated protection against future exposures, outperforming either infection or vaccination alone.
This research coincides with a summer resurgence of COVID cases, underscoring that while the pandemic’s worst phase may have passed, there remains an ongoing demand for novel strategies to mitigate and treat the virus.
The findings have been published in Cell Reports Medicine.
Scientists from the University of Texas, Texas Biomedical Research Institute, the University of North Carolina at Chapel Hill, and the Fred Hutchinson Cancer Center contributed to this research, according to futurity.org.
A patent application for SC27 has been submitted by the researchers.
The study was financially supported by the National Institutes of Health and the Bill & Melinda Gates Foundation.